The Adolescent Outpatient and Continuing Care Study (AOCCS) sponsored by Chestnut Health Systems evaluates two outpatient treatment modalities for adolescents with substance use disorders. The study's findings indicate that the Motivational Enhancement Therapy/Cognitive Behavior Therapy (MET/CBT7) without Assertive Continuing Care (ACC) is the most cost-effective intervention. This positions MET/CBT7 as a potentially strong competitor in the adolescent substance treatment market, which is increasingly focused on evidence-based, cost-effective solutions. The results may influence treatment guidelines and funding allocations, particularly in outpatient settings. The collaboration with the National Institute on Drug Abuse (NIDA) enhances credibility and may facilitate future funding opportunities or partnerships.